Further research into the molecular mechanisms underlying DIPG tumorigenesis, including the role of Tenascin-C in tumor progression and the influence of H3K27M mutations on oligodendroglial precursor cells, is necessary to identify novel therapeutic targets and improve patient outcomes. This evidence concerns the gene TNC and diffuse intrinsic pontine glioma.